CTLA4 and neoplasm: Presently, only two anti-CTLA-4 human monoclonal antibodies (Ipilimumab and Tremelimumab) are FDA-approved for use, either alone or in combination therapies, enhancing anti-tumor effects and prognosis [14,15].